Stocks News

LAST PRICE
139.2500
TODAY'S CHANGE (%)
Trending Up3.2600 (2.3972%)

Bid / Lots
139.1500/ 4
Ask / Lots
139.3900/ 4
Open / Previous Close
136.0500 / 135.9900
Day Range
Low 136.0500
High 139.3700
52 Week Range
Low 89.0400
High 148.3699
Volume
289,924
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Apr 24, 2024
- DJ Neurocrine Raised to Overweight From Equal-Weight by Wells Fargo, from 10:23AM ET on Wednesday Apr 24, 2024 by Dow Jones
  10:23AM ET on Wednesday Apr 24, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/NBIX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 24, 2024 10:23 ET (14:23 GMT)
- --Wells Fargo Upgrades Neurocrine Biosciences to Overweight From Equalweight, Price Target is $170, from 8:54AM ET on Wednesday Apr 24, 2024 by MT Newswires
  8:54AM ET on Wednesday Apr 24, 2024 by MT Newswires
  Companies Mentioned: NBIX
  08:54 AM EDT, 04/24/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contac...
- Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community, from 8:30AM ET on Wednesday Apr 24, 2024 by Dow Jones
  8:30AM ET on Wednesday Apr 24, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-launches-what-the-ch-educational-initiative-to-support-congenital-adrenal-hyperplasia-community-302125250.html
- DJ Neurocrine Is Maintained at Outperform by Oppenheimer, from 7:35AM ET on Wednesday Apr 24, 2024 by Dow Jones
  7:35AM ET on Wednesday Apr 24, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/NBIX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 24, 2024 07:35 ET (11:35 GMT)
- DJ Neurocrine Price Target Maintained With a $150.00/Share by HC Wainwright & Co., from 6:15AM ET on Wednesday Apr 24, 2024 by Dow Jones
  6:15AM ET on Wednesday Apr 24, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/NBIX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 24, 2024 06:15 ET (10:15 GMT)

Apr 25, 2024
- Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $83 From $85, Maintains Sector Perform Rating, from 11:43AM ET on Thursday Apr 25, 2024 by MT Newswires
  11:43AM ET on Thursday Apr 25, 2024 by MT Newswires
  Companies Mentioned: BMRN
- Wells Fargo Adjusts Price Target on BioMarin Pharmaceutical to $110 From $100, Maintains Overweight Rating, from 10:31AM ET on Thursday Apr 25, 2024 by MT Newswires
  10:31AM ET on Thursday Apr 25, 2024 by MT Newswires
  Companies Mentioned: BMRN
Apr 24, 2024
- BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours, from 4:23PM ET on Wednesday Apr 24, 2024 by MT Newswires
  4:23PM ET on Wednesday Apr 24, 2024 by MT Newswires
  Companies Mentioned: BMRN
- -- GUIDANCE: (BMRN) BIOMARIN PHARMACEUTICAL Forecasts Fiscal Year 2024 EPS Range $2.75 - $2.95, from 4:05PM ET on Wednesday Apr 24, 2024 by MT Newswires
  4:05PM ET on Wednesday Apr 24, 2024 by MT Newswires
  Companies Mentioned: BMRN
- -- Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 Revenue $648.8M, from 4:04PM ET on Wednesday Apr 24, 2024 by MT Newswires
  4:04PM ET on Wednesday Apr 24, 2024 by MT Newswires
  Companies Mentioned: BMRN
- -- Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 EPS $0.71, from 4:04PM ET on Wednesday Apr 24, 2024 by MT Newswires
  4:04PM ET on Wednesday Apr 24, 2024 by MT Newswires
  Companies Mentioned: BMRN
- --Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating, from 10:28AM ET on Wednesday Apr 24, 2024 by MT Newswires
  10:28AM ET on Wednesday Apr 24, 2024 by MT Newswires
  Companies Mentioned: MEDP
Apr 23, 2024
- --Jefferies Upgrades Medpace Holdings to Buy, Price Target at $450, from 7:19AM ET on Tuesday Apr 23, 2024 by MT Newswires
  7:19AM ET on Tuesday Apr 23, 2024 by MT Newswires
  Companies Mentioned: MEDP
Apr 22, 2024
- Medpace Q1 Earnings, Revenue Rise; Updates 2024 Guidance, from 4:47PM ET on Monday Apr 22, 2024 by MT Newswires
  4:47PM ET on Monday Apr 22, 2024 by MT Newswires
  Companies Mentioned: MEDP
- BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says, from 4:26PM ET on Monday Apr 22, 2024 by MT Newswires
  4:26PM ET on Monday Apr 22, 2024 by MT Newswires
  Companies Mentioned: BMRN

Neurocrine Biosciences Inc
NASDAQ:NBIXUnited States

Search Criteria

Apr 24, 2024

DJ Neurocrine Raised to Overweight From Equal-Weight by Wells Fargo, from 10:23AM ET on Wednesday Apr 24, 2024 by Dow Jones

--Wells Fargo Upgrades Neurocrine Biosciences to Overweight From Equalweight, Price Target is $170, from 8:54AM ET on Wednesday Apr 24, 2024 by MT Newswires

Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community, from 8:30AM ET on Wednesday Apr 24, 2024 by Dow Jones

DJ Neurocrine Is Maintained at Outperform by Oppenheimer, from 7:35AM ET on Wednesday Apr 24, 2024 by Dow Jones

DJ Neurocrine Price Target Maintained With a $150.00/Share by HC Wainwright & Co., from 6:15AM ET on Wednesday Apr 24, 2024 by Dow Jones

Peers Headlines

Apr 25, 2024

Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $83 From $85, Maintains Sector Perform Rating, from 11:43AM ET on Thursday Apr 25, 2024 by MT Newswires

Wells Fargo Adjusts Price Target on BioMarin Pharmaceutical to $110 From $100, Maintains Overweight Rating, from 10:31AM ET on Thursday Apr 25, 2024 by MT Newswires

Apr 24, 2024

BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours, from 4:23PM ET on Wednesday Apr 24, 2024 by MT Newswires

-- GUIDANCE: (BMRN) BIOMARIN PHARMACEUTICAL Forecasts Fiscal Year 2024 EPS Range $2.75 - $2.95, from 4:05PM ET on Wednesday Apr 24, 2024 by MT Newswires

-- Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 Revenue $648.8M, from 4:04PM ET on Wednesday Apr 24, 2024 by MT Newswires

-- Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 EPS $0.71, from 4:04PM ET on Wednesday Apr 24, 2024 by MT Newswires

--Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating, from 10:28AM ET on Wednesday Apr 24, 2024 by MT Newswires

Apr 23, 2024

--Jefferies Upgrades Medpace Holdings to Buy, Price Target at $450, from 7:19AM ET on Tuesday Apr 23, 2024 by MT Newswires

Apr 22, 2024

Medpace Q1 Earnings, Revenue Rise; Updates 2024 Guidance, from 4:47PM ET on Monday Apr 22, 2024 by MT Newswires

BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says, from 4:26PM ET on Monday Apr 22, 2024 by MT Newswires